HF1269
Coverage of medical services and prescription medications for the treatment of dementia required, and step therapy requirements for medical assistance modified.
Legislative Session 94 (2025-2026)
Related bill: SF1998
AI Generated Summary
Purpose
- Require health plan companies to cover all FDA-approved medical services and prescription medications used to treat or slow the progression of dementia.
- Require coverage for diagnostic testing to determine whether a medical service or medication is appropriate or effective for treating or slowing dementia.
- Prohibit the use of step therapy protocols when providing this dementia coverage.
Main Provisions
- Coverage scope: Health plans must cover every FDA-approved medical service and prescription medication used to treat or slow dementia, as well as related diagnostic tests to assess appropriateness or effectiveness.
- Step therapy ban: Health plans may not apply step therapy (a process that requires trying less expensive or fewer-risk options before more costly or newer treatments) for the dementia-related services and medications described.
- Legal amendments: Makes changes to Minnesota Statutes, including amending section 256B.0625 subdivision 13f and adding new provisions in Minnesota Statutes chapter 62Q (specifically 62Q.546).
Significant Changes to Existing Law
- Broadens required coverage for dementia care by mandating FDA-approved treatments and associated diagnostic testing.
- Restricts the use of step therapy for dementia treatments, limiting insurers’ ability to delay or deny access to dementia therapies.
- Introduces a new statutory provision (62Q.546) to codify these dementia coverage requirements and related protections.
Potential Impacts and Considerations
- Access: Aims to reduce barriers to dementia treatment by ensuring comprehensive coverage and timely access to therapeutics and diagnostics.
- Costs: May affect premium levels and insurer budgeting due to broader coverage requirements.
- Scope: Applies to dementia treatments approved by the FDA; does not mention non-FDA-approved or experimental therapies.
Relevant Terms dementia, FDA-approved, medical services, prescription medications, diagnostic testing, coverage, health plan company, step therapy, step therapy protocol, 62Q.184 subdivision 1, 62Q.546, Minnesota Statutes, 256B.0625 subdivision 13f, medical assistance
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| February 20, 2025 | House | Action | Introduction and first reading, referred to | Commerce Finance and Policy | |
| February 24, 2025 | House | Action | Author added | ||
| February 26, 2025 | House | Action | Author added | ||
| March 05, 2025 | House | Action | Author added | ||
| March 06, 2025 | House | Action | Authors added | ||
| Showing the 5 most recent stages. This bill has 13 stages in total. Log in to view all stages | |||||
Citations
You must be logged in to view citations.
Progress through the legislative process
In Committee
Sponsors
You must be logged in to view sponsors.